Virax Biolabs Statistics Share Statistics Virax Biolabs has 4.34M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 4.34M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 2.04% Shares Floating 3.9M Failed to Deliver (FTD) Shares 1,896 FTD / Avg. Volume 1.93%
Short Selling Information The latest short interest is 23.09K, so 0.53% of the outstanding
shares have been sold short.
Short Interest 23.09K Short % of Shares Out 0.53% Short % of Float 0.59% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.58 and the forward
PE ratio is -0.78.
Virax Biolabs's PEG ratio is
0.01.
PE Ratio -0.58 Forward PE -0.78 PS Ratio 557.69 Forward PS 82.5 PB Ratio 0.62 P/FCF Ratio -0.68 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Virax Biolabs.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.27,
with a Debt / Equity ratio of 0.07.
Current Ratio 7.27 Quick Ratio 7.13 Debt / Equity 0.07 Debt / EBITDA -0.06 Debt / FCF -0.07 Interest Coverage -105.93
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $372.41 Profits Per Employee $-356.54K Employee Count 17 Asset Turnover 0 Inventory Turnover 0.63
Taxes Income Tax -136.66K Effective Tax Rate 2.2%
Stock Price Statistics The stock price has increased by -44.12% in the
last 52 weeks. The beta is 1.64, so Virax Biolabs's
price volatility has been higher than the market average.
Beta 1.64 52-Week Price Change -44.12% 50-Day Moving Average 0.89 200-Day Moving Average 1.45 Relative Strength Index (RSI) 38.93 Average Volume (20 Days) 98,222
Income Statement In the last 12 months, Virax Biolabs had revenue of 6.33K
and earned -6.06M
in profits. Earnings per share was -1.96.
Revenue 6.33K Gross Profit -53.07K Operating Income -6.16M Net Income -6.06M EBITDA -5.8M EBIT -6.15M Earnings Per Share (EPS) -1.96
Full Income Statement Balance Sheet The company has 4.23M in cash and 377K in
debt, giving a net cash position of 3.85M.
Cash & Cash Equivalents 4.23M Total Debt 377K Net Cash 3.85M Retained Earnings -24.59M Total Assets 6.43M Working Capital 4.22M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4.56M
and capital expenditures -603.89K, giving a free cash flow of -5.17M.
Operating Cash Flow -4.56M Capital Expenditures -603.89K Free Cash Flow -5.17M FCF Per Share -1.67
Full Cash Flow Statement Margins Gross margin is -838.21%, with operating and profit margins of -97344.76% and -95739.17%.
Gross Margin -838.21% Operating Margin -97344.76% Pretax Margin -97992.31% Profit Margin -95739.17% EBITDA Margin -91649.46% EBIT Margin -97344.76% FCF Margin -81621.64%
Dividends & Yields VRAX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for VRAX is $3,
which is 294.7% higher than the current price. The consensus rating is "Buy".
Price Target $3 Price Target Difference 294.7% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 18, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Dec 18, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -9.3 Piotroski F-Score 1
